stocks logo

CTSO

Cytosorbents Corp
$
0.944
-0.056(-5.600%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.040
Open
1.020
VWAP
0.97
Vol
143.50K
Mkt Cap
59.08M
Low
0.9435
Amount
138.62K
EV/EBITDA(TTM)
--
Total Shares
54.31M
EV
61.68M
EV/OCF(TTM)
--
P/S(TTM)
1.50
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
11.46M
+13.5%
--
--
10.63M
+13.21%
--
--
9.79M
-1.1%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Cytosorbents Corporation (CTSO) for FY2025, with the revenue forecasts being adjusted by -0.71% over the past three months. During the same period, the stock price has changed by -13.43%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.71%
In Past 3 Month
Stock Price
Go Down
down Image
-13.43%
In Past 3 Month
1 Analyst Rating
up Image
5.98% Upside
Wall Street analysts forecast CTSO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTSO is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
up Image
5.98% Upside
Current: 0.944
sliders
Low
1.00
Averages
1.00
High
1.00
HC Wainwright & Co.
Sean Lee
Hold
Reiterates
$1
2025-04-03
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$10
2025-04-01
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$10
2025-01-13
Reason
D. Boral Capital says CytoSorbents reported a strong Q4, with product revenue growth estimated between 22% and 25% year-over-year. The company also demonstrated a significant gross margin rebound to around 70%, underscoring operational resilience and efficiency improvements, the analyst tells investors in a research note. D. Boral believes the results highlight CytoSorbents' strong execution and the growing demand for CytoSorb, its flagship product. The firm keeps a Buy rating on the shares with a $10 price target.
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$10
2025-01-03
Reason
D. Boral Capital says CytoSorbents reported a strong Q4, with product revenue growth estimated between 22% and 25% year-over-year. The company also demonstrated a significant gross margin rebound to around 70%, underscoring operational resilience and efficiency improvements, the analyst tells investors in a research note. D. Boral believes the results highlight CytoSorbents' strong execution and the growing demand for CytoSorb, its flagship product. The firm keeps a Buy rating on the shares with a $10 price target.
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$10
2024-11-12
Reason
HC Wainwright & Co.
Sean Lee
Hold
Reiterates
$1
2024-11-11
Reason

Valuation Metrics

The current forward P/E ratio for Cytosorbents Corp (CTSO.O) is -4.57, compared to its 5-year average forward P/E of -13.33. For a more detailed relative valuation and DCF analysis to assess Cytosorbents Corp 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-13.33
Current PE
-4.57
Overvalued PE
3.09
Undervalued PE
-29.75

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-186.75
Current EV/EBITDA
-7.92
Overvalued EV/EBITDA
304.36
Undervalued EV/EBITDA
-677.85

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
3.74
Current PS
1.54
Overvalued PS
6.48
Undervalued PS
1.00

Financials

Annual
Quarterly
FY2025Q1
YoY :
-2.92%
8.73M
Total Revenue
FY2025Q1
YoY :
-16.52%
-3.89M
Operating Profit
FY2025Q1
YoY :
-75.72%
-1.48M
Net Income after Tax
FY2025Q1
YoY :
-81.82%
-0.02
EPS - Diluted
FY2025Q1
YoY :
-29.14%
-3.51M
Free Cash Flow
FY2025Q1
YoY :
-6.97%
71.13
Gross Profit Margin - %
FY2025Q1
YoY :
-50.19%
-38.64
FCF Margin - %
FY2025Q1
YoY :
-74.99%
-16.94
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
3
47.3K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
2
168.4K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

CTSO News & Events

Events Timeline

2025-07-02 (ET)
2025-07-02
07:02:46
CytoSorbents provides FDA, Health Canada regulatory update for DrugSorb-ATR
select
2025-06-24 (ET)
2025-06-24
07:06:37
CytoSorbents files appeal with FDA for review of request for DrugSorb-ATR
select
2025-05-14 (ET)
2025-05-14
16:03:17
CytoSorbents reports Q1 EPS (2c) vs. (11c) last year
select
Sign Up For More Events

News

4.0
07-21Benzinga
A Glimpse Into The Expert Outlook On CytoSorbents Through 5 Analysts
7.0
07-02Newsfilter
CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR
7.0
07-02NASDAQ.COM
CytoSorbents Issues Regulatory Update For DrugSorb-ATR
Sign Up For More News

FAQ

arrow icon

What is Cytosorbents Corp (CTSO) stock price today?

The current price of CTSO is 0.9436 USD — it has decreased -5.6 % in the last trading day.

arrow icon

What is Cytosorbents Corp (CTSO)'s business?

arrow icon

What is the price predicton of CTSO Stock?

arrow icon

What is Cytosorbents Corp (CTSO)'s revenue for the last quarter?

arrow icon

What is Cytosorbents Corp (CTSO)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Cytosorbents Corp (CTSO)'s fundamentals?

arrow icon

How many employees does Cytosorbents Corp (CTSO). have?

arrow icon

What is Cytosorbents Corp (CTSO) market cap?